Key terms
About GMED
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GMED news
Mar 18
5:59am ET
Globus Medical upgraded to Buy from Neutral at BTIG
Mar 18
3:10am ET
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Eli Lilly & Co (LLY) and Globus Medical (GMED)
Feb 22
8:50pm ET
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Cochlear Limited (OtherCHEOF) and Nurix Therapeutics (NRIX)
Feb 22
5:06am ET
Barclays Remains a Buy on Globus Medical (GMED)
Feb 21
10:30am ET
Analysts Conflicted on These Healthcare Names: Globus Medical (GMED) and Crispr Therapeutics AG (CRSP)
Feb 21
9:26am ET
Globus Medical price target raised to $64 from $61 at Stifel
Feb 21
8:07am ET
Globus Medical: Strong Financials and Strategic Growth Post-NuVasive Merger Merit a Buy Rating
Feb 21
8:03am ET
Globus Medical (GMED) Gets a Buy from Stifel Nicolaus
Feb 21
8:00am ET
Analysts Conflicted on These Healthcare Names: Cooper Co (COO), Medtronic (MDT) and Globus Medical (GMED)
Feb 21
7:04am ET
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Universal Health (UHS) and RAPT Therapeutics (RAPT)
Feb 21
6:44am ET
Globus Medical: Hold Rating Affirmed Amidst Modest Growth Projections and Integration Risks
Feb 21
6:10am ET
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Globus Medical (GMED)
Feb 21
5:31am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Globus Medical (GMED) and Zai Lab (ZLAB)
Feb 20
4:34pm ET
Globus Medical backs FY24 EPS view $2.68 to $2.70, consensus $2.69
Feb 20
4:32pm ET
Globus Medical reports Q4 EPS 60c, consensus 61c
Feb 16
8:07am ET
Stifel Nicolaus Sticks to Their Buy Rating for Globus Medical (GMED)
Feb 06
5:02am ET
Globus Medical Promotes Keith Pfeil to COO and CFO
Feb 05
4:33pm ET
Globus Medical promotes Keith Pfeil as COO and Chief Financial Officer
Jan 22
7:02am ET
Globus Medical price target raised to $79 from $77 at Canaccord
Jan 11
8:16am ET
Globus Medical Soars with Strong Q4 Results and Promising Post-Merger Outlook: Buy Rating Affirmed
Jan 11
8:01am ET
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), SAGE Therapeutics (SAGE) and Globus Medical (GMED)
Jan 11
7:28am ET
RBC Capital Sticks to Its Buy Rating for Globus Medical (GMED)
Jan 11
6:56am ET
Piper Sandler Remains a Hold on Globus Medical (GMED)
Jan 11
6:37am ET
Globus Medical: Hold Rating Amidst Strong Performance and Cautious Outlook
Jan 11
5:46am ET
Globus Medical Hold Rating: Balanced Q4 Performance Offset by NUV A Integration Concerns and Modest Growth Outlook
Jan 11
5:21am ET
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Globus Medical (GMED) and AbbVie (ABBV)
Jan 11
5:05am ET
Globus Medical: A Hold Rating Amidst Encouraging Performance and Stable Outlook
Jan 10
4:36pm ET
Globus Medical sees FY24 EPS $2.68 to $2.70, consensus $2.72
Jan 10
4:34pm ET
Globus Medical reports preliminary FY23 revenue $1.57B, consensus $1.55B
Jan 10
4:33pm ET
Globus Medical sees Q4 revenue $615.5M, consensus $602.26M
Jan 10
7:10am ET
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Neurocrine (NBIX) and Globus Medical (GMED)
No recent news articles are available for GMED
No recent press releases are available for GMED
GMED Financials
Key terms
Ad Feedback
GMED Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GMED Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range